Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.
- DOI
- 10.1007/s00280-011-1724-7
- Published
- 2012 Feb
- Container
- Cancer chemotherapy and pharmacology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s00280-011-1724-7,
title = {Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.},
author = {Lam ET and Goel S and Schaaf LJ and Cropp GF and Hannah AL and Zhou Y and McCracken B and Haley BI and Johnson RG and Mani S and Villalona-Calero MA},
year = {2012},
journal = {Cancer chemotherapy and pharmacology},
doi = {10.1007/s00280-011-1724-7},
url = {https://doi.org/10.1007/s00280-011-1724-7}
}RIS
TY - JOUR TI - Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors. AU - Lam ET AU - Goel S AU - Schaaf LJ AU - Cropp GF AU - Hannah AL AU - Zhou Y AU - McCracken B AU - Haley BI AU - Johnson RG AU - Mani S AU - Villalona-Calero MA PY - 2012 JO - Cancer chemotherapy and pharmacology DO - 10.1007/s00280-011-1724-7 UR - https://doi.org/10.1007/s00280-011-1724-7 ER -
APA
ET, L., S, G., LJ, S., GF, C., AL, H., Y, Z., B, M., BI, H., RG, J., S, M., & MA, V. (2012). Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors.. Cancer chemotherapy and pharmacology. https://doi.org/10.1007/s00280-011-1724-7
Source records
- pubmed · retrieved 2026-09-26T20:50:25.357Z